Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084884 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 18
- Study locations
NCT06084884: Active Phase 1 study of Hepatocellular Carcinoma, sponsored by AstraZeneca.
NCT06084884 is a Phase 1 study of Hepatocellular Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 94 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (63% lower). The trial reports 18 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06084884, a Phase 1 study of Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 18
- Study locations
Study Summary
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Primary Outcome
Determine if treatment with AZD5851 is safe and tolerable through assessment of DLTs, AEs, SAEs and changes from baseline in vital signs, ECGs, and laboratory parameters
Conditions Studied
Interventions
- BIOLOGICAL AZD5851
Study Locations (18)
California
- Research Site - Duarte
- Research Site - Orange
- Research Site - San Francisco
Other
- Research Site - Kashiwa
- Research Site - Osakasayama-shi
- Research Site - Seoul
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Arizona
- Research Site - Phoenix
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - Jacksonville
Georgia
- Research Site - Atlanta
Kansas
- Research Site - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-12-14 |
| Est. Completion | 2027-12-13 |
| Phase | Phase 1 |
What the registry record for NCT06084884 still lists
NCT06084884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which AZD5851 is the first listed.
NCT06084884 lists 18 locations in 13 states (California, Other, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT06084884 about?
NCT06084884 is a clinical study titled "A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma". A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
What is the current status of trial NCT06084884?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-12-14. Estimated completion is 2027-12-13.
What conditions does trial NCT06084884 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06084884?
The interventions under investigation include: AZD5851 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06084884?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06084884 being conducted?
This trial has 18 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06084884's enrollment target sits among peer trials
94 66th of 145 higher than 80 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI